Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialys… (NCT07765030) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department
This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026.
Medical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor/inotropic support, intensive care unit admission, length of stay, and hospital outcomes.
The primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor/inotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18 years or older.
* Followed in the critical care area of the Emergency Department of Antalya
* Training and Research Hospital between January 1, 2023, and August 1, 2026.
* Presence of an indication for emergency renal replacement therapy.
* Underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the emergency department.
* Required critical care-level monitoring or management.
* Availability of sufficient demographic, clinical, laboratory, and in-hospital outcome data in the hospital information system, electronic medical records, laboratory records, or clinical follow-up notes.
Exclusion Criteria:
* Age younger than 18 years.
* Renal replacement therapy initiated outside the emergency department.
* Presentation only for routine chronic hemodialysis at the hospital dialysis unit without receiving renal replacement therapy in the emergency department.
* Renal replacement therapy planned in the emergency department but HD or CVVHDF could not be performed.
* Missing essential clinical, laboratory, or in-hospital outcome data. In patients with repeated emergency department admissions, only the first emergency renal replacement therapy episode will be included to reduce statistical dependency.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
In-Hospital Mortality
Timeframe: Up to 30 days from emergency department admission